JERUSALEM, April 4, 2018 /PRNewswire/ -- Intec Pharma LTD (NASDAQ: NTEC) (TASE: NTEC) ("Intec" or "the Company") today announces that data collected from the Company's Phase 2 development program of its proprietary Accordion Pill™ oral drug delivery system have been accepted for poster presentation

JERUSALEM, April 3, 2018 /PRNewswire/ -- Intec Pharma Ltd . (NASDAQ: NTEC) (TASE: NTEC), a clinical stage biopharmaceutical company focused on developing pharmaceutical therapies based on its proprietary  Accordion Pill™  platform technology, today announced it will host a Key Opinion Leader (KOL)

JERUSALEM, March 26, 2018 /PRNewswire/ -- Intec Pharma LTD (NASDAQ, TASE: NTEC) ("Intec" or "the Company") today announces the appointment of Roger J. Pomerantz, M.D., F.A.C.P. to its Board of Directors. Dr. Pomerantz is President, Chief Executive Officer and Chairman of the Board of Directors of

Global leader in formulation and film technology manufacture to establish commercial scale production capabilities for Intec's lead product candidate in FDA compliant facility JERUSALEM, March 12, 2018 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ, TASE: NTEC) ("Intec" or the "Company") today announces

More than 300 patients enrolled in pivotal Phase 3 ACCORDANCE Trial Gastroscopy safety sub-study successfully completed JERUSALEM, March 9, 2018 /PRNewswire/ --   Intec Pharma LTD (NASDAQ: NTEC) (TASE: NTEC) today announces financial results for the three and twelve months ended December 31,

JERUSALEM, March 5, 2018 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC), a clinical-stage biopharmaceutical company focused on developing pharmaceutical therapies based on its proprietary Accordion Pill™ platform technology, today announced that the Company's officers will provide a corporate

Industry Veteran brings over 30 years of experience in drug development JERUSALEM, Jan. 31, 2018 /PRNewswire/ --   Intec Pharma Ltd. (NASDAQ:  NTEC) (TASE:  NTEC ), a clinical stage biopharmaceutical company focused on developing pharmaceutical therapies based on its proprietary Accordion

JERUSALEM, January 8, 2018 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: NTEC), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, today announced it has entered into a Feasibility and Option agreement with

JERUSALEM, January 3, 2018 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: NTEC), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill TM  platform technology, today announced that the Canadian Intellectual Property Office has issued

· Closed equity offering of $57.5 million; Cash of $64.7 million at September 30, 2017 · Expanding planned enrollment to 420 patients in its Phase 3 ACCORDANCE Trial; enrollment to be completed in the third quarter of 2018 · Formed new U.S. Medical Affairs and U.S.